Key Takeaways:
Innovent Biologics reported first-half product revenue of RMB8.2 billion, up 55 percent from a year earlier, sending its shares higher in Hong Kong trading.
The company's interim results announcement showed second-quarter product revenue exceeded RMB4.3 billion, up about 60 percent year over year, according to the disclosure.
Shares opened 2.48 percent higher and peaked at HKD92.20 before last trading at HKD88.55, up 2.13 percent, with 4.34 million shares changing hands for HKD393 million in turnover. Short selling accounted for HKD80.81 million, or 9.44 percent of the day's activity.
The acceleration on a multi-billion-yuan base shows Innovent's commercial execution is strengthening as its oncology and immunology portfolio matures. The growth rate outpaces several Hong Kong-listed biotech peers, including BeiGene and Jiangsu Hengrui Pharmaceuticals, which have reported slower product revenue expansion in recent quarters.
Innovent, a Suzhou-based biopharmaceutical company, has built its commercial lineup around PD-1 inhibitor Tyvyt and a pipeline spanning oncology, cardiovascular, and metabolic diseases. The company has expanded its sales force and in-licensed assets to broaden coverage beyond its flagship immunotherapy, with product revenue now the dominant driver of its top line. Its commercial portfolio has grown to include multiple marketed drugs across China, supported by partnerships with global drugmakers including Eli Lilly.
The company has not yet disclosed full interim net profit, margin, or dividend details. Investors will watch the complete first-half report for those figures, along with updates on pipeline milestones and any guidance for the second half. The strong product revenue print could support a re-rating of the stock, which has traded in line with the broader Hang Seng Healthcare Index this year. A sustained beat would also reinforce confidence in the wider Hong Kong biotech sector, which has drawn renewed inflows as China's drug pricing reforms ease.
This article is for informational purposes only and does not constitute investment advice.
